5 Most Promising Cancer Stocks According to Analysts

2. Puma Biotechnology, Inc. (NASDAQ:PBYI)

Number of Hedge Fund Holders: 14

Average Price Target Based on Analyst Ratings: 100.25%

Puma Biotechnology, Inc. (NASDAQ:PBYI) was founded in 2010 and is headquartered in Los Angeles, California. It is a biopharmaceutical company, focused on the development and commercialization of products to improve cancer care in the United States and internationally. It is one of the most promising cancer stocks, with an average target upside potential of over 100%. 

On August 5, H.C. Wainwright analyst Edward White reiterated a Buy recommendation on Puma Biotechnology, Inc. (NASDAQ:PBYI) but lowered the firm’s price target on the shares to $8 from $12. 

According to Insider Monkey’s fourth quarter database, 14 hedge funds were bullish on Puma Biotechnology, Inc. (NASDAQ:PBYI), compared to 13 funds in the prior quarter. Kamran Moghtaderi’s Eversept Partners is the biggest position holder in the company, with 1.50 million shares worth $6.3 million. 

Follow Puma Biotechnology Inc. (NYSE:PBYI)